AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on SY... (equal to 5 percent of patients regardles...)

AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on SYMBICORT(R)

Date:12/11/2008

equal to 5 percent of patients, regardless of relationship to treatment, included nasopharyngitis, headache, upper respiratory tract infection, pharyngolaryngeal pain, sinusitis, and stomach discomfort.

Please see full Prescribing Information and visit www.MySYMBICORT.com.

Media Contacts US:

Michele Meeker 610-662-3589 (24 hours)

Media Contacts UK:

Neil McCrae +44 207 304 5045 (24 hours)
Chris Sampson +44 207 304 5130 (24 hours)

    Investor Enquiries UK:
    Jonathan Hunt      +44 207 304 5087        mob: +44 7775 704032
    Mina Blair         +44 207 304 5084        mob: +44 7718 581021
    Karl Hard          +44 207 304 5322        mob: +44 7789 654364

    Investor Enquiries US:
    Ed Seage                   +1 302 886 4065       mob: +1 302 373 1361
    Jorgen Winroth             +1 212 579 0506       mob: +1 917 612 4043
    Peter Vozzo (MedImmune)    +1 301 398 4358       mob: +1 301 252 7518

About AstraZeneca

AstraZeneca (NYSE: AZN) is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.35 billion dollar healthcare business with 12,200 employees committed to improving people's lives. AstraZeneca is listed in the Dow
'/>"/>

1

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
5. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
6. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
7. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
8. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
9. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
10. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
11. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six

Post Your Comments:

AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on SY...(equal to 5 percent of patients regardles...),Health